Urogen Pharma Ltd
URGN21.350USD
+0.830+4.04%
終値 02/06, 16:00（ET）15分遅れの株価
998.78M時価総額
損失額直近12ヶ月PER
詳細情報 Urogen Pharma Ltd 企業名
UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).
Urogen Pharma Ltdの企業情報
企業コードURGN
会社名Urogen Pharma Ltd
上場日May 04, 2017
最高経営責任者「CEO」Barrett (Elizabeth A)
従業員数235
証券種類Ordinary Share
決算期末May 04
本社所在地9 Ha'ta'asiya St
都市RA'ANANA
証券取引所NASDAQ OMX - NASDAQ BASIC
国Israel
郵便番号4365007
電話番号97297707601
ウェブサイトhttps://www.urogen.com/
企業コードURGN
上場日May 04, 2017
最高経営責任者「CEO」Barrett (Elizabeth A)
Urogen Pharma Ltdの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Arie S. Belldegrun, M.D.
Dr. Arie S. Belldegrun, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
408.69K
--
Ms. Elizabeth A. (Liz) Barrett
Ms. Elizabeth A. (Liz) Barrett
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
326.69K
--
Mr. Jason Drew Smith
Mr. Jason Drew Smith
Chief Compliance Officer, General Counsel, Corporate Secretary
Chief Compliance Officer, General Counsel, Corporate Secretary
43.30K
+1813.00%
Mr. Christopher (Chris) Degnan
Mr. Christopher (Chris) Degnan
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
2.28K
+2280.00%
Ms. Cynthia M. Butitta
Ms. Cynthia M. Butitta
Independent Director
Independent Director
2.00K
+2000.00%
Dr. Stuart Holden, M.D.
Dr. Stuart Holden, M.D.
Independent Director
Independent Director
--
--
Dr. Mark P. Schoenberg, M.D.
Dr. Mark P. Schoenberg, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Vincent Perrone
Mr. Vincent Perrone
Investor Relations
Investor Relations
--
--
Dr. Leana S. Wen, M.D.
Dr. Leana S. Wen, M.D.
Independent Director
Independent Director
--
--
Mr. Daniel G. Wildman
Mr. Daniel G. Wildman
Independent Director
Independent Director
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Arie S. Belldegrun, M.D.
Dr. Arie S. Belldegrun, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
408.69K
--
Ms. Elizabeth A. (Liz) Barrett
Ms. Elizabeth A. (Liz) Barrett
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
326.69K
--
Mr. Jason Drew Smith
Mr. Jason Drew Smith
Chief Compliance Officer, General Counsel, Corporate Secretary
Chief Compliance Officer, General Counsel, Corporate Secretary
43.30K
+1813.00%
Mr. Christopher (Chris) Degnan
Mr. Christopher (Chris) Degnan
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
2.28K
+2280.00%
Ms. Cynthia M. Butitta
Ms. Cynthia M. Butitta
Independent Director
Independent Director
2.00K
+2000.00%
Dr. Stuart Holden, M.D.
Dr. Stuart Holden, M.D.
Independent Director
Independent Director
--
--
収益内訳
通貨: USD更新時刻: Tue, Jan 6
通貨: USD更新時刻: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
事業別USD
会社名
収益
比率
Jelmyto
25.70M
93.53%
Zusduri
1.78M
6.47%
会社から関連データがまだ開示されていません。
事業別
地域別
事業別USD
会社名
収益
比率
Jelmyto
25.70M
93.53%
Zusduri
1.78M
6.47%
株主
更新時刻: Sat, Feb 7
更新時刻: Sat, Feb 7
株主統計
種類
株主統計
株主統計
比率
RTW Investments L.P.
9.71%
Paradigm BioCapital Advisors LP
9.01%
TD Securities, Inc.
6.82%
Morgan Stanley & Co. LLC
5.25%
Jefferies LLC
4.70%
他の
64.52%
株主統計
株主統計
比率
RTW Investments L.P.
9.71%
Paradigm BioCapital Advisors LP
9.01%
TD Securities, Inc.
6.82%
Morgan Stanley & Co. LLC
5.25%
Jefferies LLC
4.70%
他の
64.52%
種類
株主統計
比率
Hedge Fund
29.37%
Research Firm
22.98%
Investment Advisor
22.01%
Investment Advisor/Hedge Fund
19.50%
Insurance Company
4.14%
Individual Investor
2.09%
Corporation
1.79%
Private Equity
1.47%
Bank and Trust
0.25%
機関投資家保有株
更新時刻: Thu, Jan 1
更新時刻: Thu, Jan 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q4
320
48.56M
103.75%
-13.57M
2025Q3
311
45.66M
97.55%
-6.58M
2025Q2
285
53.00M
114.72%
+5.27M
2025Q1
290
49.25M
108.64%
+1.67M
2024Q4
280
43.94M
103.24%
-1.94M
2024Q3
262
44.13M
104.63%
-2.19M
2024Q2
247
46.02M
111.40%
+11.07M
2024Q1
255
34.96M
99.86%
+5.57M
2023Q4
237
29.16M
94.80%
+4.33M
2023Q3
238
25.93M
86.41%
+2.69M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
RTW Investments L.P.
4.54M
9.71%
--
--
Sep 30, 2025
Paradigm BioCapital Advisors LP
4.22M
9.01%
+1.88M
+80.79%
Sep 30, 2025
TD Securities, Inc.
3.19M
6.82%
--
--
Sep 30, 2025
Morgan Stanley & Co. LLC
2.46M
5.25%
+983.01K
+66.65%
Sep 30, 2025
Jefferies LLC
2.20M
4.7%
--
--
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
2.14M
4.58%
+33.75K
+1.60%
Sep 30, 2025
SilverArc Capital Management, LLC
1.58M
3.37%
-445.20K
-22.01%
Sep 30, 2025
Millennium Management LLC
1.47M
3.14%
+874.71K
+147.25%
Sep 30, 2025
UBS Asset Management Switzerland AG
1.32M
2.82%
--
--
Jan 31, 2025
Acorn Capital Advisors, LLC
1.26M
2.69%
--
--
Sep 30, 2025
詳細を見る
関連ETF
更新時刻: Sat, Dec 6
更新時刻: Sat, Dec 6
銘柄名
比率
ARK Israel Innovative Technology ETF
2.09%
Tema Oncology ETF
1.92%
ALPS Medical Breakthroughs ETF
0.39%
Hypatia Women CEO ETF
0.28%
ProShares Ultra Nasdaq Biotechnology
0.16%
iShares Micro-Cap ETF
0.15%
Fidelity Enhanced Small Cap ETF
0.11%
Vanguard US Momentum Factor ETF
0.1%
Invesco Nasdaq Biotechnology ETF
0.09%
iShares Biotechnology ETF
0.07%
詳細を見る
ARK Israel Innovative Technology ETF
比率2.09%
Tema Oncology ETF
比率1.92%
ALPS Medical Breakthroughs ETF
比率0.39%
Hypatia Women CEO ETF
比率0.28%
ProShares Ultra Nasdaq Biotechnology
比率0.16%
iShares Micro-Cap ETF
比率0.15%
Fidelity Enhanced Small Cap ETF
比率0.11%
Vanguard US Momentum Factor ETF
比率0.1%
Invesco Nasdaq Biotechnology ETF
比率0.09%
iShares Biotechnology ETF
比率0.07%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
配当落ち日
種類
比率
データなし
日付
配当落ち日
種類
比率
データなし
